# Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

> **NCT00536874** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** oxaliplatin
- **GENETIC:** protein expression analysis
- **GENETIC:** proteomic profiling
- **OTHER:** diagnostic laboratory biomarker analysis
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00536874
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2012-09
- **Final completion:** 2017-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536874, "Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00536874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*